SCHEMBL17351373

SCHEMBL17351373

N#Cc1c(N)nc2c(c1-c1ccccc1)CCCCC2

nearest known ligand 0.97

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 17/20 0.97
HSD17B10 Q99714 8/20 0.97
ALDH1A1 P00352 10/20 0.92
ADORA2A P29274 2/20 0.92
SMN1; SMN2 Q16637 1/20 0.92
HPGD P15428 10/20 0.80
NPSR1 Q6W5P4 1/20 0.78
MEN1 O00255 2/20 0.76
KMT2A Q03164 2/20 0.76
TSHR P16473 3/20 0.75
HTT P42858 1/20 0.75
CYP1A2 P05177 1/20 0.73
CYP3A4 P08684 1/20 0.73
CYP2C9 P11712 1/20 0.73
CYP2C19 P33261 1/20 0.73
MDM2 Q00987 1/20 0.73
USP2 O75604 4/20 0.69
GAA P10253 1/20 0.65
MAPT P10636 1/20 0.64
ADORA1 P30542 1/20 0.61

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6252358 0.99 KDM4E (1.00) KDM4EHSD17B10ALDH1A1ADORA2ASMN1; SMN2
SCHEMBL1177057 0.96 KDM4E (1.00) KDM4EHSD17B10ALDH1A1ADORA2ASMN1; SMN2
SCHEMBL6250232 0.88 KDM4E (0.79) KDM4EHSD17B10ALDH1A1ADORA2ASMN1; SMN2
SCHEMBL31120389 0.86 KDM4E (0.78) KDM4EHSD17B10ALDH1A1ADORA2ASMN1; SMN2
SCHEMBL6252385 0.86 KDM4E (1.00) KDM4EHSD17B10ALDH1A1ADORA2ASMN1; SMN2
SCHEMBL31120380 0.85 KDM4E (0.76) KDM4EHSD17B10ALDH1A1ADORA2ASMN1; SMN2
SCHEMBL17351540 0.84 KDM4E (0.71) KDM4EHSD17B10ALDH1A1ADORA2ASMN1; SMN2
SCHEMBL6252484 0.83 KDM4E (0.73) KDM4EHSD17B10ALDH1A1ADORA2ASMN1; SMN2
SCHEMBL6250908 0.82 KDM4E (0.92) KDM4EHSD17B10ALDH1A1ADORA2ASMN1; SMN2
SCHEMBL16295335 0.82 KDM4E (0.71) KDM4EHSD17B10ALDH1A1ADORA2ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9562052-B2 Bicyclicpyridine derivatives HOFFMANN-LA ROCHE INC. (US) 2017-02-07 US disclosed
US-9562052-B2 Bicyclicpyridine derivatives HOFFMANN-LA ROCHE INC. (US) 2017-02-07 US disclosed
US-9562052-B2 Bicyclicpyridine derivatives HOFFMANN-LA ROCHE INC. (US) 2017-02-07 US disclosed
EP-2888245-B1 NEW BICYCLICPYRIDINE DERIVATIVES HOFFMANN LA ROCHE (CH) 2016-09-21 EP disclosed
EP-2888245-B1 NEW BICYCLICPYRIDINE DERIVATIVES HOFFMANN LA ROCHE (CH) 2016-09-21 EP disclosed
US-20150368256-A1 NEW BICYCLICPYRIDINE DERIVATIVES HOFFMANN-LA ROCHE INC. (US) 2015-12-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150368256-A1 NEW BICYCLICPYRIDINE DERIVATIVES CACNA1E, CHRM1, CHRM2 KDM4E 2736/4885HSD17B10 3662/4885ALDH1A1 774/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.